NasdaqCM - Delayed Quote USD

Leap Therapeutics, Inc. (LPTX)

3.2500 +0.0800 (+2.52%)
At close: April 26 at 4:00 PM EDT
3.2000 -0.05 (-1.54%)
After hours: April 26 at 6:55 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
1,500.0000
1,500.0000
Operating Expense
85,940.0000
85,940.0000
54,712.0000
41,700.0000
29,808.0000
Operating Income
-85,940.0000
-85,940.0000
-54,712.0000
-40,200.0000
-28,308.0000
Net Non Operating Interest Income Expense
4,027.0000
4,027.0000
871.0000
-32.0000
54.0000
Other Income Expense
499.0000
499.0000
-608.0000
-379.0000
738.0000
Pretax Income
-81,414.0000
-81,414.0000
-54,449.0000
-40,611.0000
-27,516.0000
Tax Provision
--
--
147.0000
-24.0000
-2.0000
Net Income Common Stockholders
-81,414.0000
-81,414.0000
-54,596.0000
-40,587.0000
-37,588.0000
Diluted NI Available to Com Stockholders
-81,414.0000
-81,414.0000
-54,596.0000
-40,587.0000
-37,588.0000
Basic EPS
-3.98
--
-4.82
-4.70
-6.30
Diluted EPS
-3.98
--
-4.82
-4.70
-6.30
Basic Average Shares
20,445.1090
--
11,323.9090
8,582.5280
5,932.7710
Diluted Average Shares
20,445.1090
--
11,323.9090
8,582.5280
5,932.7710
Total Operating Income as Reported
-87,041.0000
-87,041.0000
-56,763.0000
-41,426.0000
-28,539.0000
Total Expenses
85,940.0000
85,940.0000
54,712.0000
41,700.0000
29,808.0000
Net Income from Continuing & Discontinued Operation
-81,414.0000
-81,414.0000
-54,596.0000
-40,587.0000
-27,514.0000
Normalized Income
-81,413.0000
-81,413.0000
-53,988.0000
-40,208.0000
-28,252.0000
Interest Income
4,027.0000
4,027.0000
925.0000
9.0000
93.0000
Interest Expense
--
--
54.0000
41.0000
39.0000
Net Interest Income
4,027.0000
4,027.0000
871.0000
-32.0000
54.0000
EBIT
-81,414.0000
-81,414.0000
-54,395.0000
-40,570.0000
-27,477.0000
EBITDA
-81,399.0000
-81,399.0000
-54,379.0000
-40,541.0000
-27,443.0000
Reconciled Depreciation
15.0000
15.0000
16.0000
29.0000
34.0000
Net Income from Continuing Operation Net Minority Interest
-81,414.0000
-81,414.0000
-54,596.0000
-40,587.0000
-27,514.0000
Total Unusual Items Excluding Goodwill
-1.0000
-1.0000
-608.0000
-379.0000
738.0000
Total Unusual Items
-1.0000
-1.0000
-608.0000
-379.0000
738.0000
Normalized EBITDA
-81,398.0000
-81,398.0000
-53,771.0000
-40,162.0000
-28,181.0000
12/31/2020 - 1/25/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PDSB PDS Biotechnology Corporation
3.2700
+0.31%
 
MDNAF Medicenna Therapeutics Corp.
1.8200
+30.00%
 
CRVS Corvus Pharmaceuticals, Inc.
1.4500
-2.03%
 
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
 
MREO Mereo BioPharma Group plc
2.7400
-2.49%
 
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
 
VINC Vincerx Pharma, Inc.
0.7300
-18.59%
 
OCUL Ocular Therapeutix, Inc.
4.7450
+12.98%
 
XFOR X4 Pharmaceuticals, Inc.
1.1650
+3.10%
 
ELEV Elevation Oncology, Inc.
3.6200
-0.69%